TGFB1 and breast carcinoma: In summary, pre-clinical studies in several different syngeneic as well as allogeneic mammary cancer models have provided convincing evidence that targeting the TGF-β pathway using either a TGF-β neutralizing antibody or receptor kinase inhibitors can inhibit both early lung and bone metastases of basal-like breast cancer.